Data on Monoclonal Antibodies Detailed by a Researcher at University of Genoa (Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy).

A report from the University of Genoa discusses the role of thymic stromal lymphopoietin (TSLP) in the immune response to environmental insults and its involvement in chronic diseases such as asthma and chronic rhinosinusitis. The report highlights the potential of monoclonal antibodies, specifically Tezepelumab, in targeting TSLP and preventing its interactions with receptors. Clinical trials are currently underway to evaluate the safety and efficacy of Tezepelumab in various inflammatory disorders. This research provides valuable insights into the functional role of TSLP and its suitability as a target for biological therapies. [Extracted from the article]